Brokerages Set Seres Therapeutics Inc (MCRB) Price Target at $16.00

Shares of Seres Therapeutics Inc (NASDAQ:MCRB) have been assigned an average rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company.

Several equities research analysts have weighed in on MCRB shares. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a report on Friday, February 8th. ValuEngine downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Oppenheimer reissued a “buy” rating on shares of Seres Therapeutics in a report on Tuesday. BidaskClub downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 13th. Finally, Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 9th.

In related news, insider Eric D. Shaff sold 4,378 shares of the business’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $5.75, for a total value of $25,173.50. Following the sale, the insider now owns 17,220 shares in the company, valued at approximately $99,015. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas Desrosier sold 5,471 shares of the business’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $5.75, for a total value of $31,458.25. Following the completion of the sale, the executive vice president now owns 21,525 shares in the company, valued at approximately $123,768.75. The disclosure for this sale can be found here. Corporate insiders own 37.10% of the company’s stock.

Several hedge funds have recently bought and sold shares of MCRB. Great West Life Assurance Co. Can purchased a new stake in Seres Therapeutics during the 4th quarter worth about $30,000. Two Sigma Investments LP purchased a new stake in Seres Therapeutics during the 4th quarter worth about $82,000. Rhumbline Advisers increased its holdings in Seres Therapeutics by 48.8% during the 4th quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 8,895 shares during the period. Paloma Partners Management Co purchased a new stake in Seres Therapeutics during the 3rd quarter worth about $147,000. Finally, Jefferies Group LLC increased its holdings in Seres Therapeutics by 75.5% during the 3rd quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 9,215 shares during the period. Hedge funds and other institutional investors own 77.26% of the company’s stock.

MCRB stock traded down $0.06 during trading on Thursday, reaching $6.70. 155,218 shares of the company traded hands, compared to its average volume of 365,165. Seres Therapeutics has a 12 month low of $4.42 and a 12 month high of $9.75. The company has a market cap of $277.50 million, a P/E ratio of -2.76 and a beta of 1.82.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.15. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 350.03%. The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $3.78 million. On average, sell-side analysts predict that Seres Therapeutics will post -1.79 EPS for the current fiscal year.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Recommended Story: Why do corrections happen?

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.